BBOT Q4 2024 Earnings — BridgeBio Oncology Therapeutics Inc. Revenue & Financial Results | Market Cap Arena

BBOTBridgeBio Oncology Therapeutics Inc.

$820M

Q4 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$22M

Net Income

-$20M

EPS (Diluted)

$0.12

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$87,859

Free Cash Flow

-$87,859

Stock-Based Comp.

$77,400

Balance Sheet

Total Assets

$194M

Total Liabilities

$6M

Stockholders' Equity

$189M

Cash & Equivalents

$2M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$22M	-$41,692	-52377.7%
Net Income	-$20M	-$41,692	-47120.1%